Skip to main content
. 2022 Jan 10;40(9):956–967. doi: 10.1200/JCO.21.01693

FIG 4.

FIG 4.

CD22 site density. (A) Surface CD22 site density measured using ABC at baseline and after cycle 1 in 13 patients with residual leukemia after cycle 1. (B) Surface CD22 expression (CD22%) at baseline and after cycle 1 in 13 patients with residual leukemia after cycle 1, demonstrating decrease from baseline in eight of 13 patients. ABC, antibody bound per cell.